Joscha Borho

Mr. Joscha Borho

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2023 in Toxins
Verified
Journal Article
Open access
PDF file
SHSebastian Heber
Sebastian Heber
JBJoscha Borho
Joscha Borho
NSNicole Stadler
Nicole Stadler
FWFanny Wondany
Fanny Wondany
IKIrina König
Irina König
MFMaximilian Fellermann
Maximilian Fellermann
The binary Clostridium (C.) botulinum C2 toxin consists of two non-linked proteins. The proteolytically activated binding/transport subunit C2IIa forms barrel-shaped homoheptamers, which bind to cell surface receptors, mediate endocytosis, and translocate the enzyme subunit C2I into the cytosol of target cells. Here, we investigate whether C2IIa can be harnessed as a transporter for proteins/enzymes fused to polycationic tags, as earlier demonstrated for the related anthrax toxin transport subunit PA63. To test C2IIa-mediated transport in cultured cells, reporter enzymes are generated by fusing different polycationic tags to the N- or C-terminus of other bacterial toxins’ catalytic A subunits. C2IIa as well as PA63 deliver N-terminally polyhistidine-tagged proteins more efficiently compared to C-terminally tagged ones. However, in contrast to PA63, C2IIa does not efficiently deliver polylysine-tagged proteins into the cytosol of target cells. Moreover, untagged enzymes with a native cationic N-terminus are efficiently transported by both C2IIa and PA63. In conclusion, the C2IIa-transporter serves as a transport system for enzymes that harbor positively charged amino acids at their N-terminus. The charge distribution at the N-terminus of cargo proteins and their ability to unfold in the endosome and subsequently refold in the cytosol determine transport feasibility and efficiency.

6 June 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
LXLujuan Xu
Lujuan Xu
MSMaria J. S. A. Silva
Maria J. S. A. Silva
JCJaime Coelho
Jaime Coelho
JBJoscha Borho
Joscha Borho
NSNicole Stadler
Nicole Stadler
TWTanja Weil
Tanja Weil
Chemoselective dual functionalization of proteins has emerged as an invaluable tool to introduce two distinct payloads to proteins, thus greatly expanding their structural and functional repertoire for more advanced biomedical applications. Here, we introduce N-alkylpyridinium reagents as soft electrophiles for chemoselective dual modification of cysteine residues in peptides or proteins via a 1,6-addition reaction. The N-alkylpyridinium derivatives can be synthesized in two reaction steps revealing good water solubility, high labelling efficiency and chemoselectivity towards cysteine over lysine/N-terminal amine residues, even when used in large excess. This reaction can be combined with strain-promoted azide-alkyne click (SPAAC) and inverse-electron-demand Diels−Alder (iEDDA) reactions to achieve dual functionalization of proteins in a sequential simple one-pot reaction. As a proof-of-concept, the Rho-inhibiting enzyme Clostridium botulinum C3 is functionalized with a cancer cell-targeting peptide and a fluorescent dye for the inhibition of specific Rho-mediated intracellular pathways. The high stability, ease of synthesis, fast reaction kinetics, high water-solubility and chemoselectivity make N-alkylpyridinium reagents unique for dual modification of peptides and proteins to increase their functional diversities for medical applications.

22 April 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
TWTanja Weil
Tanja Weil
SKSeah Ling Kuan
Seah Ling Kuan
LXLujuan Xu
Lujuan Xu
MSMaria Maria J. S. A. Silva
Maria Maria J. S. A. Silva
JCJaime Coelho
Jaime Coelho
Holger BarthHolger Barth
Holger Barth
We report N-alkylpyridinium reagents for site-selective dual modification of proteins via a regioselective 1,6-thiol addition reaction. The N-alkylpyridinium derivatives can be syn-thesized in two reaction steps and demonstrate high labelling efficiency and chemose-lectivity towards cysteine residues. This reaction is combined with strain-promoted azide-alkyne click and inverse-electron-demand Diels−Alder reactions to achieve dual functionalization of proteins in a sequential one-pot reaction. A Rho-inhibiting enzyme is functionalized with a cancer cell-targeting peptide and a fluorescent dye for successful in vitro uptake imaging and concomitant inhibition of specific Rho-mediated cellular pathways. The ease of synthesis, fast kinetics, high solubility and regioselectivity make N-alkylpyridinium reagents unique for protein/peptide modification to increase their functional diversities for medical applications.

Verified
Journal Article
Open access
PDF file
NSNicole Stadler
Nicole Stadler
BGBingjie Gao
Bingjie Gao
MSMaria Maria J. S. A. Silva
Maria Maria J. S. A. Silva
JBJoscha Borho
Joscha Borho
EHEva Haunschild
Eva Haunschild
Holger BarthHolger Barth
Holger Barth
Metastatic breast carcinoma (BC) cells are prone to spreading in the bone microenvironment, leading to a vicious cycle between local osteoclast-mediated osteolysis and tumor progression. Therefore, the targeted pharmacological down-modulation of BC cell proliferation as well as osteoclast differentiation and hyperactivity might represent a promising treatment option. We developed a multifunctional peptide nanocarrier combining bioactive EPI-X4 peptides and the Rho-inhibiting C3bot enzyme from Clostridium botulinum. C3bot is preferentially internalized into the cytosol of monocytic cells, including osteoclasts, where it inhibits Rho-mediated signal transduction. However, Rho-mediated cellular processes like migration and cell division can also be inhibited in non-monocytic cells if C3bot is delivered into their cytosol by a nanocarrier. To accomplish this, we designed a supramolecular transporter where one molecule of biotinylated C3bot and three biotinylated entities of the human EPI-X4 peptide-derived CXCR4 antagonist JM173 are assembled on avidin as a central platform. This modular transport system (JM173)3-Avi-C3 down-modulated osteoclast formation and hyperactivity and delivered the therapeutic cargo C3bot successfully into the cytosol of breast cancer cells, where it inhibited Rho.